NCT00869973TerminatedPhase 3
Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study
S. Maria Hospital, Terni1 site in 1 country580 target enrollmentStarted: September 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Sponsor
- Enrollment
- 580
- Locations
- 1
- Primary Endpoint
- Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration
Study Overview
Brief Summary
The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast cancer patients.
Detailed Description
This is a phase III, double-blind, randomized trial, to evaluated the efficacy and safety of aprepitant for the prevention of delayed emesis in patients with breast cancer submitted for the first time to chemotherapy with cyclophosphamide plus anthracyclines.
The study will be carried out during the first cycle of chemotherapy.
For the prevention of acute emesis, all patients will receive, before chemotherapy:
- dexamethasone 8 mg iv in 15 minutes, 30 minutes before chemotherapy;
- palonosetron 0.25 mg iv bolus, 30 minutes before chemotherapy
- aprepitant 125 mg orally, 60 minutes before chemotherapy
After 24 hours from chemotherapy administration, patients will be randomized to receive:
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients with breast cancer, receiving for the first time chemotherapy with cyclophosphamide + anthracyclines (FAC, FEC, AC, EC).
- •patients over 18 years old and those who signed informed consent
- •adequate contraception if premenopausal women
- •Every other anticancer drug in the first 24 hours will be administered after the end of cyclophosphamide plus anthracycline.
Exclusion Criteria
- •patients already submitted to chemotherapy
- •patients receiving any chemotherapy on days 2-4 after treatment
- •patients with concomitant severe diseases or with predisposition to emesis such as intestinal obstruction, active peptic ulcer, hypercalcemia and brain metastases
- •contraindications to corticosteroids (i.e., active peptic ulcer or previous bleeding from peptic ulcer
- •patients submitted to concomitant radiotherapy or submitted to radiotherapy in the 15 days before chemotherapy or planned to receive radiotherapy during the 8 days after chemotherapy
- •patients receiving other concomitant antiemetic treatments or submitted to antiemetic treatments in the 24 hours before chemotherapy
- •patients with nausea or vomiting in the 24 hours before chemotherapy
- •patients receiving concomitant steroids, except when administered at physiologic doses
- •patients receiving concomitant benzodiazepines, except when used for nocturnal sedation
- •patients with WBC count <3000/mm3 or platelet count <70000/mm3
- •patients who are pregnant or breast-feeding
Arms & Interventions
1
Experimental
Aprepitant
Intervention: Aprepitant (Drug)
2
Active Comparator
dexamethasone
Intervention: dexamethasone (Drug)
Outcomes
Primary Outcomes
Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration
Time Frame: 6 days
Secondary Outcomes
- Evaluation of the impact on quality of life of the two antiemetic regimens(6 days)
- Evaluation of the prognostic factors of delayed emesis in patients receiving a combination of aprepitant, palonosetron and dexamethasone for the prevention of acute emesis(6 days)
Investigators
Roila Fausto
Dr
S. Maria Hospital, Terni
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 3
Aprepitant in the Prevention of Cisplatin-induced Delayed EmesisEmesisNCT00869310S. Maria Hospital, Terni303
Completed
Phase 4
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having CraniotomyPostoperative Nausea and VomitingNCT00734929Duke University115
Completed
Not Applicable
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantChronic Myeloproliferative DisordersGestational Trophoblastic TumorMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsNausea and VomitingTesticular Germ Cell TumorBreast CancerOvarian CancerLymphomaLeukemiaNeuroblastomaNCT00293384Barbara Ann Karmanos Cancer Institute40
Completed
Not Applicable
comparision between Aprepitant and Dexamethasone For Preventing Postoperative Nausea And Vomiting In Breast Cancer PatientsCTRI/2014/12/005333AIIMS160
Unknown
Phase 3
Aprepitant for the Prevention of Chemotherapy-induced Nausea and VomitingChemotherapy-induced Nausea and VomitingNCT02933099Wuhan Union Hospital, China300